Inhibition of stromal biglycan promotes normalization of the tumor microenvironment and enhances chemotherapeutic efficacy.
Li CongNako MaishiDorcas A AnnanMarian F YoungHirofumi MorimotoMasahiro MorimotoJin-Min NamYasuhiro HidaKyoko HidaPublished in: Breast cancer research : BCR (2021)
Our results suggest that targeting stromal biglycan may yield a potent and superior anticancer effect in breast cancer.
Keyphrases